Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly.

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say ...

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say that's only a short-term solution to its ailing business.

Shares of Weight Watchers parent company WW International (WW) rose nearly 40% after the company announced plans to begin ...

In addition to availability, the cost of weight loss drugs like Wegovy and Zepbound is a major barrier preventing many ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

WeightWatchers stock rises after the company announces compounded semaglutide offerings, addressing GLP-1 shortages while ...

High demand has created a market for compounded versions of the drug best known as Ozemic or Wegovy, but doctors and the FDA ...

WeightWatchers recently announced the inclusion of compounded semaglutide into its suite of offerings. This new clinical weight management intervention aims to broaden access for eligible members who ...

Still, more than a quarter of employers are considering adding coverage for GLP-1 drugs for weight loss in 2025 or 2026, ...

WeightWatchers (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) announced today the addition of compounded semaglutide into its offering, broadening eligible members’ access to clinical weight ...